Search

Reducing the sulfur content in high-sulfur petroleum coke (HSPC) has become an urgent issue, however, remains a great challenge with the development of petroleum refining industry. Herein, a highly-efficient catalyst quaternary ammonium phosphotungstate ionic liquid [(C4H9)4N]3PW12O40 (C4@HPA) was initiated to activate H2O2, and the sulfur content of HSPC was remarkably decreased from 4.46 wt.% to 2.76 wt.% at a relatively mild temperature (70 oC), which is discernible below than 1400 oC in industry. The characterization results showed that only sulfate can be removed, while sulfoxide and sulfone were retained in petroleum coke. Moreover, the desulfurization activity of C4@HPA/H2O2 to thiophene sulfides decreases as follows: Thiophene > 2-Methylthiophene > 2,5-Dimethylthiophene > Dibenzothiophene > 4-Methyldibenzothiophene. It reveals that the sulfur of 4-MDBT is the most difficult to be removed. Therefore, this founding here may shine light on the understanding and construction of efficient catalyst for desulfurization of high-sulfur petroleum coke in industry. [ABSTRACT FROM AUTHOR]

The increasing numbers of cases of wound disease are now posing a big challenge in China. For more convenience of wound patients, wound management in community health care centers under the supervision of a specialist at general hospitals is an ideal solution. To ensure an accurate diagnosis in community health clinics, it is important that “the same language” for wound description, which may be composed of unified format description, including wound image, must be achieved. We developed a wound information management system that was built up by acquisition terminal, wound description, data bank, and related software. In this system, a 3G mobile phone was applied as acquisition terminal, which could be used to access to the data bank. This documentation system was thought to be an appropriate proposal for community wound care because of its objectivity, uniformity, and facilitation. It also provides possibility for epidemiological study in the future. [ABSTRACT FROM AUTHOR]

Purpose: This meta-analysis was designed to evaluate the clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) conducted utilizing stents of different diameters, thus providing recommendations for more logical selections of covered stents for patients with portal hypertension, in particular for the Asian population., Materials and Methods: Web of Science, PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure and Wan Fang were searched for randomized controlled trials and cohort studies from inception until February 2023. The meta-analysis was carried out using Revman 5.4 Software. Heterogeneity between researches was assessed by the χ2 test and I2 index. The outcomes evaluated were the incidence of post-TIPS hepatic encephalopathy (HE), variceal rebleeding, shunt dysfunction, 1-year overall survival and decrease in portal pressure gradient (PPG)., Results: Eight appropriate clinical trials with 1246 patients were selected (638 and 608 patients in the experimental and control groups, respectively). In regards to preoperative PPG reduction, there was no discernible difference between the two groups [mean difference = 1.15, 95% confidence interval (CI) = -0.29-2.58, P = 0.12]. The rate of post-TIPS HE was significantly higher in patients in the 8 mm stent group than in the 6-7 mm stent group [odds ratio (OR) = 0.54, 95% CI = 0.42-0.70, P < 0.00001, I2 = 46%]. There were no significant differences in the rates of variceal rebleeding (OR = 1.05, 95% CI = 0.67-1.65, P = 0.84, I2 = 0%), shunt dysfunction (OR = 0.88, 95% CI = 0.53-1.47, P = 0.64, I2 = 0%) and 1-year overall survival (OR = 0.86, 95% CI = 0.50-1.50, P = 0.61, I2 = 0%)., Conclusion: Asian populations with portal hypertension may benefit more from TIPS with 6-7 mm covered stents because they can reduce the risk of postoperative HE while offering similar efficacy when compared to 8 mm covered stents., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

With the growth of aging society, China has become the country of population with the highest incidence of diabetes in the world. Diabetes leads to pathological changes in vascular and nervous system, rendering the diabetic skin fragile and hard to heal if wounded; in the end most diabetic wounds tend to become chronic skin ulcers. The refractory diabetic wound is the result of various endogenous and exogenous factors. It is a quite complicated pathophysiologic event which lacks an effective and specific therapeutic method in clinic. The use of stem cells could be a new approach of treating diabetic chronic wounds since they have a potential ability of self-renovation and multi-directional differentiation which will promote angiogenesis and wound healing process, thus be beneficial in the care of ischemia diseases of the lower limb. This article reviews basic theory of treating diabetic wound and the changes in microenvironment, and prompts many successful cases in curing refractory diabetic wounds.

Objective: To review the research progress in the treatment of bone defect or osteomyelitis with drug-carried bionic nano-bone so as to offer some theoretic supports and experimental references for those relative researchers., Methods: The related literature was reviewed. The research progress in the treatment of bone defect or osteomyelitis with drug-carried bionic nano-bone was analyzed, which included the designing and preparing of drug-carried nano composites, the way of making infected bone defect animal models, and the general steps, test indexes and results., Results: Traumatic osteomyelitis and bone defect were two kinds of disease to difficulty cure in nowadays clinical orthopaedics. The osteomyelitis, especially chronic one was quite troublesome during the treatments. Many researchers made artificial bone with nano-materials and added drugs into them by various ways for the purpose of controlling infection and repairing bone defection simultaneously. But these researches were still at the laboratory phase, lacking the criterions of making relative animal models, and needed to be improved in the way of drug slow-releasing and nano-scaffold producing., Conclusion: The drug-carried bionic nano-bone as a kind of newly emerging replacement material has splendid effects in the treatments of traumatic large area bone defect or osteomyelitis and will have a brilliant future.